Abivax S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAVXF research report →
About the company
Abivax S. A. , a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer.
- CEO
- Marc de Garidel
- IPO
- 2016
- Employees
- 69
- HQ
- Paris, FR
Price Chart
- Market Cap
- $6.39B
- P/E
- -27.93
- P/S
- 0.00
- P/B
- 20.62
- EV/EBITDA
- -41.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.19%
- ROIC
- -45.51%
- Revenue
- $0 · -100.00%
- Net Income
- $-335,976,116 · -90.63%
- EPS
- $-4.83 · -72.50%
- Op Income
- $-250,531,130
- FCF YoY
- -4.82%
- 52W High
- $133.40
- 52W Low
- $7.28
- 50D MA
- $106.95
- 200D MA
- $110.26
- Beta
- -0.21
- Avg Volume
- 27
Get TickerSpark's AI analysis on AAVXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AAVXF coverage
Recent articles, reports, and earnings notes.
No research on AAVXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AAVXF report →Similar companies
Peers in the same neighborhood.